Trilostane

• CAT Number: A000679
• CAS Number: 13647-35-3
• Molecular Formula: C20H27NO3
• Molecular Weight: 329.4
• Purity: ≥95%
• Synonyms: 13647-35-3; Vetoryl; Trilostanum; Desopan; Trilostano
• Target: Dehydrogenase
• Solubility: >16.4mg/mL in DMSO
• Storage: -20°C
• InChI: 1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1
• InChIKey: KVJXBPDAXMEYOA-CXANFOAXSA-N
• SMILES: CC12CCC3C(C1CCC2O)CCC45C3(CC(=C(C4O5)O)C#N)C

Trilostane is an inhibitor of 3β-hydroxysteroid dehydrogenase used in the treatment of Cushing/’s syndrome. It was withdrawn from the United States market in April 1994. However, it was recently approved in 2008 for the treatment of Cushing/’s disease (hyperandrenocorticism) in dogs. It is also the first drug approved to treat both pituitary- and adrenal-dependent Cushing/’s in dogs. This prescription drug works by stopping the production of cortisol in the adrenal glands.

Reference

1: Crosby J, Brown S. Stability of compounded trilostane suspension in cod liver
oil. Vet J. 2017 Oct;228:15-17. doi: 10.1016/j.tvjl.2017.10.001. Epub 2017 Oct 5.
PubMed PMID: 29153102.

2: Sieber-Ruckstuhl N, Salesov E, Quante S, Riond B, Rentsch K, Hofmann-Lehmann
R, Reusch C, Boretti F. Effects of Trilostane on urinary Catecholamines and their
metabolites in dogs with Hypercortisolism. BMC Vet Res. 2017 Sep 4;13(1):279.
doi: 10.1186/s12917-017-1187-0. PubMed PMID: 28870207; PubMed Central PMCID:
PMC5583971.

3: Nagata N, Kojima K, Yuki M. Comparison of Survival Times for Dogs with
Pituitary-Dependent Hyperadrenocorticism in a Primary-Care Hospital: Treated with
Trilostane versus Untreated. J Vet Intern Med. 2017 Jan;31(1):22-28. doi:
10.1111/jvim.14617. Epub 2016 Dec 1. PubMed PMID: 27906457; PubMed Central PMCID:
PMC5259634.

4: Macfarlane L, Parkin T, Ramsey I. Pre-trilostane and three-hour
post-trilostane cortisol to monitor trilostane therapy in dogs. Vet Rec. 2016 Dec
10;179(23):597. doi: 10.1136/vr.103744. Epub 2016 Nov 1. PubMed PMID: 27803375;
PubMed Central PMCID: PMC5256409.

5: Boretti FS, Holzthüm J, Reusch CE, Sieber-Ruckstuhl NS. Lack of association
between clinical signs and laboratory parameters in dogs with
hyperadrenocorticism before and during trilostane treatment. Schweiz Arch
Tierheilkd. 2016 Sep;158(9):631-638. doi: 10.17236/sat00083. PubMed PMID:
27655162.

6: Woolcock AD, Bugbee AC, Creevy KE. Evaluation of baseline cortisol
concentration to monitor efficacy of twice-daily administration of trilostane to
dogs with pituitary-dependent hyperadrenocorticism: 22 cases (2008-2012). J Am
Vet Med Assoc. 2016 Apr 1;248(7):814-21. doi: 10.2460/javma.248.7.814. PubMed
PMID: 27003023.

7: Oda H, Mori A, Shono S, Onozawa E, Sako T. The effect of 1 year of trilostane
treatment on peripheral lymphocyte subsets in dogs with pituitary-dependent
hyperadrenocorticism. J Vet Med Sci. 2016 Jun 1;78(5):851-4. doi:
10.1292/jvms.15-0410. Epub 2016 Jan 17. PubMed PMID: 26782012; PubMed Central
PMCID: PMC4905842.

8: Midence JN, Drobatz KJ, Hess RS. Cortisol Concentrations in Well-Regulated
Dogs with Hyperadrenocorticism Treated with Trilostane. J Vet Intern Med. 2015
Nov-Dec;29(6):1529-33. doi: 10.1111/jvim.13615. Epub 2015 Sep 16. PubMed PMID:
26374943; PubMed Central PMCID: PMC4895678.

9: Fracassi F, Corradini S, Floriano D, Boari A, Aste G, Pietra M, Bergamini PF,
Dondi F. Prognostic factors for survival in dogs with pituitary-dependent
hypercortisolism treated with trilostane. Vet Rec. 2015 Jan 10;176(2):49. doi:
10.1136/vr.102546. Epub 2014 Aug 28. PubMed PMID: 25170036.

10: Bonadio CM, Feldman EC, Cohen TA, Kass PH. Comparison of adrenocorticotropic
hormone stimulation test results started 2 versus 4 hours after trilostane
administration in dogs with naturally occurring hyperadrenocorticism. J Vet
Intern Med. 2014 Jul-Aug;28(4):1239-43. doi: 10.1111/jvim.12357. Epub 2014 May
26. PubMed PMID: 24863172; PubMed Central PMCID: PMC4857938.